Some evidence suggests that the increase of AChE is one of the important causes of AD (Lahiri et al., 2002; Racchi, Sironi, Caprera, König, & Govoni, 2001), and currently, clinically available AChE inhibitors for AD, such as donepezil, galantamine, and rivastigmine, can ameliorate the cognitive symptoms and enhance the living quality for AD patients. Here, ACHE is linked to Alzheimer disease.